Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in MDS, AA, or T-LGL
NCT01191749Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2010
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in myelodysplastic syndrome (MDS), aplastic anemia, T-cell large granular lymphocytic leukemia, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2010; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
myelodysplastic syndrome (MDS)aplastic anemiaT-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT01191749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191749.